Literature DB >> 10792283

Expression of HLA-C-specific natural killer cell receptors (CD158a and CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation.

J Tanaka1, A Mori, S Ohta, Y Yamamoto, S Kobayashi, S Hashino, M Kobayashi, M Asaka, M Imamura.   

Abstract

We investigated the expression of natural killer cell receptors (NKRs) for HLA-C on peripheral blood mononuclear cells (PBMCs) in 23 allogeneic bone marrow transplantation (allo-BMT) patients to analyse the role of NKRs in alloresponse concerning graft-versus-host disease (GVHD). CD158a expression was low and there was little change in the expression after allo-BMT. Also, there was no difference in the proportion of CD158a+/CD3- after allo-BMT. In contrast, the proportion of CD158b+/CD3- cells, mainly NK cells, increased in the early stage (< 2 months) after allo-BMT and then gradually decreased (3.3 +/- 2.6% before BMT vs. 15.4 +/- 8. 6% in the early stage after BMT, 8.5 +/- 4.9% during the period 3-6 months after BMT and 7.0 +/- 3.0% > 6 months after BMT; P < 0.05). However, CD158b expression on CD3+ T cells increased 3 months after allo-BMT (1.1 +/- 1.1% before BMT vs. 5.1 +/- 7.7% during the period 3-6 months after BMT and 3.0 +/- 2.4% > 6 months after BMT, P < 0. 05). The highest percentages of CD158 expression in patients without chronic GVHD (cGVHD) and those with cGVHD were compared. The percentage of CD158b+/CD3+ cells and also that of CD158b+/CD8+ cells were significantly increased in patients with cGVHD compared with those in patients without cGVHD (2.6 +/- 2.0% vs. 8.0 +/- 11.2% and 2.3 +/- 1.5% vs. 8.3 +/- 11.7% respectively; P < 0.05). The exact clinical relevance of these CD158b-expressing cells is not clear. However, there is an interesting possibility that CD158b-expressing cells play some role in the regulation of GVHD after allo-BMT.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792283     DOI: 10.1046/j.1365-2141.2000.01938.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

Review 2.  Immunological reconstitution and immunoregulatory cells in hematopoietic stem cell transplantation.

Authors:  Masahiro Imamura
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Authors:  Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

Review 4.  Immunoregulatory cells for transplantation tolerance and graft-versus-leukemia effect.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

Review 5.  New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.

Authors:  H Joachim Deeg
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

Review 6.  Present and Future of Allogeneic Natural Killer Cell Therapy.

Authors:  Okjae Lim; Mi Young Jung; Yu Kyeong Hwang; Eui-Cheol Shin
Journal:  Front Immunol       Date:  2015-06-03       Impact factor: 7.561

Review 7.  CAR-NK Cells: From Natural Basis to Design for Kill.

Authors:  Muhammad Babar Khawar; Haibo Sun
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.